Abstract
Introduction: Underutilization of evidence-based medications in patients (pts) with HF has been previously described; however, little is known about the use of beta blockers (BBs) or angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in pts following cardiac device procedures. Therefore, we assessed drug prescriptions among pts with an implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy with or without ICD (CRT) in a large contemporary national managed care database.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
